Valsartan in the Treatment of Heart Attack Survivors

References

• [ACE] ACE Inhibitor Myocardial Infarction Collaborative GroupIndications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trialsCirculation1998972202129631869
   PubMedGoogle Scholar
• AguilarDSolomonSDKoberLNewly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialCirculation20041101572815364810
   PubMed Web of Science ®Google Scholar
• AikawaYRohdeLPlehnJRegional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysisAm Heart J20011412344211174337
   PubMed Web of Science ®Google Scholar
• [AIRE] The Acute Infarction Ramipril Efficacy (AIRE) Study InvestigatorsEffect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failureLancet199334282188104270
   PubMed Web of Science ®Google Scholar
• AmbrosioniEBorghiCMagnaniBThe Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study InvestigatorsThe effect of the angiotensin-converting–enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarctionN Engl J Med19953328057990904
   PubMed Web of Science ®Google Scholar
• BaruchLAnandICohenISAugmented short- and longterm hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study GroupCirculation19999926586410338459
   PubMed Web of Science ®Google Scholar
• BenzJOshrainCHenryDValsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazideJ Clin Pharmacol19973710179055135
   PubMed Web of Science ®Google Scholar
• BuhlerFRLaraghJHBaerLPropranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renindependent hypertensive diseasesN Engl J Med19722871209145084985
   PubMed Web of Science ®Google Scholar
• CampbellDJAggarwalAEslerMβ-blockers, angiotensin II, and ACE inhibitors in patients with heart failureLancet200135816091011716889
   PubMed Web of Science ®Google Scholar
• CampbellDJKrumHEslerMDLosartan increases bradykinin levels in hypertensive humansCirculation20051113152015655136
   PubMed Web of Science ®Google Scholar
• CarsonPTognoniGCohnJNEffect of Valsartan on hospitalization: results from Val-HeFTJ Card Fail200391647112815565
   PubMed Web of Science ®Google Scholar
• ChioleroABurnierMPharmacology of valsartan, an angiotensin II receptor antagonistExpert Opin Investig Drugs19987191525
   PubMedGoogle Scholar
• ChungOCsikosTUngerTAngiotensin II receptor pharmacology and AT1-receptor blockersJ Hum Hypertens199913Suppl 1S112010076916
   PubMedGoogle Scholar
• CohnJNAnandISLatiniRValsartan Heart Failure Trial InvestigatorsSustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure TrialCirculation20031081306912939207
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGValsartan Heart Failure Trial InvestigatorsA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med200134516677511759645
   PubMed Web of Science ®Google Scholar
• [CONSENSUS] The CONSENSUS Trial Study GroupEffects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)N Engl J Med19873161429352883575
   PubMed Web of Science ®Google Scholar
• CoreaLCardoniOFogariRValsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipineClin Pharmacol Ther19966034168841157
   PubMed Web of Science ®Google Scholar
• CriscioneLde GasparoMBuhlmayerPPharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtypeBr J Pharmacol1993110761718242249
   PubMed Web of Science ®Google Scholar
• de GasparoMHessPClozelMCombination of low-dose valsartan and enalapril improves endothelial dysfunction and coronary reserve in Nomega-nitro-L-arginine methyl ester-treated spontaneously hypertensive ratsJ Cardiovasc Pharmacol20024078980012409988
   PubMed Web of Science ®Google Scholar
• de GasparoMLevensNDoes blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme?Pharmacol Toxicol199882257719677617
   PubMedGoogle Scholar
• DicksteinKKjekshusJOPTIMAAL Steering Committee of the OPTIMAAL Study GroupEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanLancet20023607526012241832
   PubMed Web of Science ®Google Scholar
• DrexlerHEndothelial dysfunction in heart failure and potential for reversal by ACE inhibitionBr Heart J1994723 SupplS11147946797
   PubMedGoogle Scholar
• DzauVJTissue renin-angiotensin system in myocardial hypertrophy and failureArch Intern Med1993153937428386920
   PubMed Web of Science ®Google Scholar
• DzauVJTheodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesisHypertension20013710475211304501
   PubMed Web of Science ®Google Scholar
• FerrarioCMJessupJChappellMCEffect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2Circulation200511126051015897343
   PubMed Web of Science ®Google Scholar
• FerrarioCMTraskAJJessupJAAdvances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular functionAm J Physiol2005289H228190
   PubMed Web of Science ®Google Scholar
• FlatherMDYusufSKoberLACE-Inhibitor Myocardial Infarction Collaborative GroupLong-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patientsLancet200035515758110821360
   PubMed Web of Science ®Google Scholar
• [GISSI-3] Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto MiocardicoGISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarctionLancet19943431115227910229
   PubMed Web of Science ®Google Scholar
• [GISSI-3] Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto MiocardicoSix-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarctionJ Am Coll Cardiol199627337448557903
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSCHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362772613678870
   PubMed Web of Science ®Google Scholar
• HamroffGKatzSDManciniDAddition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failureCirculation199999990210051289
   PubMed Web of Science ®Google Scholar
• HowesLGTranDCan angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?Drug Saf20022573611888349
   PubMed Web of Science ®Google Scholar
• IshiyamaYGallagherPEAverillDBUpregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptorsHypertension200443970615007027
   PubMed Web of Science ®Google Scholar
• ISIS-4 (Fourth International Study of Infarct Survival) Collaborative GroupISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarctionLancet1995345669857661937
   PubMed Web of Science ®Google Scholar
• IwataMCowlingRTGurantzDAngiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effectsAm J Physiol2005289H235663
   PubMed Web of Science ®Google Scholar
• JongPDemersCMcKelvieRSAngiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trialsJ Am Coll Cardiol2002394637011823085
   PubMed Web of Science ®Google Scholar
• JordeUPEnnezatPVLiskerJMaximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failureCirculation2000101844610694521
   PubMed Web of Science ®Google Scholar
• JugduttBIMyocardial salvage by intravenous nitroglycerin in conscious dogs: loss of beneficial effect with marked nitroglycerin-induced hypotensionCirculation198368673846409447
   PubMed Web of Science ®Google Scholar
• JugduttBIIntravenous nitroglycerin unloading in acute myocardial infarctionAm J Cardiol19916852D63D
   PubMed Web of Science ®Google Scholar
• JugduttBIPrevention of ventricular remodelling post myocardial infarction: timing and duration of therapyCan J Cardiol19939103148439824
   PubMed Web of Science ®Google Scholar
• JugduttBIDhallaNSBeamishRENaganoMModification of left ventricular remodelling after myocardial infarctionThe failing heart1995New YorkRaven Pr23145
   Google Scholar
• JugduttBIPrevention of ventricular remodeling after myocardial infarction and in congestive heart failureHeart Failure Rev1996111529
   Google Scholar
• JugduttBICrawfordMHAngiotensin II receptor blockersCardiology Clinics Annual of Drug Therapy1998Vol 2PhiladelphiaWB Saunders Pub117
   Google Scholar
• JugduttBIRemodeling of the myocardium and potential targets in the collagen degradation and synthesis pathwaysCurr Drug Targets Cardiovasc Haematol Disord2003a313012769643
   PubMedGoogle Scholar
• JugduttBIVentricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?Circulation2003b108139540312975244
   PubMed Web of Science ®Google Scholar
• JugduttBIBalghithMEnhanced regional AT2-receptor and PKCɛ expression during cardioprotection induced by AT1-receptor blockade after reperfused myocardial infarctionJ Renin Angiotensin Aldosterone Syst200121344011881113
   PubMed Web of Science ®Google Scholar
• JugduttBIMenonVAT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarctionMol and Cell Biochem2004a2601111815228092
   PubMed Web of Science ®Google Scholar
• JugduttBIMenonVValsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat in vivo models of reperfused myocardial infarctionJ Cardiac Failure2004b107482
   PubMed Web of Science ®Google Scholar
• JugduttBISawickiGAT1 receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction. Detection using proteomicsMol and Cell Biochem20042631798815524179
   PubMed Web of Science ®Google Scholar
• JugduttBIWarnicaJWIntravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: effect of timing, dosage and infarct locationCirculation198878906193139326
   PubMed Web of Science ®Google Scholar
• JugduttBIWarnicaJWTolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarctionAm J Cardiol19896458172506751
   PubMedGoogle Scholar
• JugduttBIXuYBalghithMCardioprotection induced by AT1R blockade after reperfused myocardial infarction: association with regional increase in AT2R, IP3R and PKCɛ proteins and cGMPJ Cardiovasc Pharmacol Ther200053011111150400
   PubMedGoogle Scholar
• JuliusSKjeldsenSEWeberMfor the VALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• KawamuraMImanashiMMatsushimaYCirculating angiotensin II levels under repeated administration of lisinopril in normal subjectsClin Exp Pharmacol Physiol199219547531326422
   PubMed Web of Science ®Google Scholar
• KoberLTorp-PedersenCCarlsenJEA clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study GroupN Engl J Med1995333167067477219
   PubMed Web of Science ®Google Scholar
• LangtryHDMcClellanKJValsartan/hydrochlorothiazideDrugs199957751510353300
   PubMed Web of Science ®Google Scholar
• LatiniRMassonSAnandIValsartan Heart Failure Trial InvestigatorsEffects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)Circulation20021062454812417542
   PubMed Web of Science ®Google Scholar
• LeeVCRhewDCDylanMMeta-analysis: angiotensinreceptor blockers in chronic heart failure and high-risk acute myocardial infarctionAnn Intern Med200414169370415520426
   PubMed Web of Science ®Google Scholar
• LeriALiuYLiBUp-regulation of AT1 and AT2 receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell deathAm J Pathol200015616637210793077
   PubMed Web of Science ®Google Scholar
• LevyBICan angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin systemCirculation200410981314707017
   PubMed Web of Science ®Google Scholar
• LishengLLiuLSWangWChinese Cardiac Study Collaborative GroupOral captopril versus placebo among 13 634 patients with suspected acute myocardial infarctio: interim report from the Chinese Cardiac Study (CCS-1)Lancet199534568677885123
   PubMed Web of Science ®Google Scholar
• LiuYHYangXPSharovVGEffects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptorsJ Clin Invest1997991926359109437
   PubMed Web of Science ®Google Scholar
• LootAERoksAJHenningRHAngiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in ratsCirculation200210515485011927520
   PubMed Web of Science ®Google Scholar
• MaggioniAPAnandIGottliebSOVal-HeFT Investigators (Valsartan Heart Failure Trial)Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensinconverting enzyme inhibitorsJ Am Coll Cardiol20024014142112392830
   PubMed Web of Science ®Google Scholar
• MaggioniAPLatiniRCarsonPEVal-HeFT InvestigatorsValsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Am Heart J20051495485715864246
   PubMed Web of Science ®Google Scholar
• MarkhamAGoaKLValsartan. A review of its pharmacology and therapeutic use in essential hypertensionDrugs1997542993119257084
   PubMed Web of Science ®Google Scholar
• McKelvieRSYusufSPericakDComparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study InvestigatorsCirculation199910010566410477530
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKCHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet20033627677113678869
   PubMed Web of Science ®Google Scholar
• McMurrayJAngiotensin receptor blockers and myocardial infarction: Analysis of evidence is incomplete and inaccurate. Rapid responseBMJ2005330126915920134
   PubMedGoogle Scholar
• ModenaMGAvetaPMenozziAAldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarctionAm Heart J200114141611136485
   PubMed Web of Science ®Google Scholar
• NewRBSampsonACKingMKEffects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performanceCirculation200010214475310993866
   PubMed Web of Science ®Google Scholar
• O'ConnellJBThe economic burden of heart failureClin Cardiol200023Suppl III6103
   Google Scholar
• OpieLHSackMNEnhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypesCirc Res200188654811304486
   PubMed Web of Science ®Google Scholar
• PfefferJMPfefferMABraunwaldEInfluence of chronic captopril therapy on the infarcted left ventricle of the ratCirc Res19855784953891127
   PubMed Web of Science ®Google Scholar
• PfefferMAACE inhibitors in acute myocardial infarction: patient selection and timingCirculation199897219249631866
   PubMedGoogle Scholar
• PfefferMABraunwaldEVentricular remodeling after myocardial infarction. Experimental observations and clinical implicationsCirculation1990811161722138525
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyéLASAVE InvestigatorsEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med1992327669771386652
   PubMed Web of Science ®Google Scholar
• PfefferMAGreavesSCArnoldJMEarly versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trialCirculation1997952643519193433
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan in Acute Myocardial Infarction Trial InvestigatorsValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349189390614610160
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBCHARM Investigators and CommitteesEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet20033627596613678868
   PubMed Web of Science ®Google Scholar
• PittBPoole-WilsonPASegalREffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE IILancet20003551582710821361
   PubMed Web of Science ®Google Scholar
• PittBRemmeWZannadFEplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study InvestigatorsEplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med200334813092112668699
   PubMed Web of Science ®Google Scholar
• PittBSegalRMartinezFARandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Lancet1997349747529074572
   PubMed Web of Science ®Google Scholar
• PittBWhiteHNicolauJEPHESUS InvestigatorsEplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failureJ Am Coll Cardiol2005464253116053953
   PubMed Web of Science ®Google Scholar
• PittBZannadFRemmeWJThe effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study InvestigatorsN Engl J Med19993417091710471456
   PubMed Web of Science ®Google Scholar
• SawickiGJugduttBIDetection of changes in protein levels in the in vivo canine model of acute heart failure following ischemiareperfusion injury – Functional proteomics studiesProteomics20044219520215221779
   PubMed Web of Science ®Google Scholar
• SawickiGMenonVJugduttBIImproved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockadeJ Cardiac Failure2004104429
   PubMed Web of Science ®Google Scholar
• SeyediNXuXNasjlettiACoronary kinin generation mediates nitric oxide release after angiotensin receptor stimulationHypertension199526164707607720
   PubMed Web of Science ®Google Scholar
• SharpeNBenefit of beta-blockers for heart failure: proven in 1999Lancet19993531988910376609
   PubMed Web of Science ®Google Scholar
• SolomonSDGlynnRJGreavesSRecovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy studyAnn Intern Med2001134451811255520
   PubMed Web of Science ®Google Scholar
• SolomonSDSkaliHAnavekarNSChanges in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarctionCirculation200511134111915967846
   PubMed Web of Science ®Google Scholar
• [SOLVD] The SOLVD InvestigatorsEffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failureN Engl J Med19913252933022057034
   PubMed Web of Science ®Google Scholar
• [SOLVD] The SOLVD InvestigatorsEffect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractionsN Engl J Med1992327685911463530
   PubMed Web of Science ®Google Scholar
• SpinaleFGde GasparoMWhitebreadSModulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systemsCirculation1997962385969337215
   PubMed Web of Science ®Google Scholar
• St John SuttonMPfefferMAPlappertTSAVE InvestigatorsQuantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captoprilCirculation19948968758281697
   PubMed Web of Science ®Google Scholar
• SuzukiGMoritaHMishimaTEffects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failureCirculation200210629677212460880
   PubMed Web of Science ®Google Scholar
• SwedbergKHeldPKjekshusJCONSENSUS Study GroupEffects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)N Engl J Med1992327678841495520
   PubMed Web of Science ®Google Scholar
• SzummerKESolomonSDVelazquezEJVALIANT RegistryHeart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registryEur Heart J20052621141915972293
   PubMed Web of Science ®Google Scholar
• TimmermansPBCariniDJChiuATThe discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonistsAm J Hypertens19914275S81S1854452
   PubMed Web of Science ®Google Scholar
• TomBde VriesRSaxenaPRBradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and Ndomain blockadeHypertension20013895911463767
   PubMed Web of Science ®Google Scholar
• UrataHHealyBStewartRWAngiotensin II-forming pathways in normal and failing human heartsCirc Res199066883902156635
   PubMed Web of Science ®Google Scholar
• VelazquezEJFrancisGSArmstrongPWVALIANT registryAn international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registryEur Heart J20042519111915522470
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFGattobigioRDo angiotensin II receptor blockers increase the risk of myocardial infarction?Eur Heart J2005262381616081468
   PubMed Web of Science ®Google Scholar
• VerheijenIFierensFLDebackerJPInteraction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptorsFundam Clin Pharmacol2000145778511206708
   PubMed Web of Science ®Google Scholar
• VermaSStraussMAngiotensin receptor blockers and myocardial infarctionBMJ20043291248915564232
   PubMed Web of Science ®Google Scholar
• WellingtonKFauldsDMValsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertensionDrugs2002621983200512215069
   PubMed Web of Science ®Google Scholar
• WongMJohnsonGShabetaiREchocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies GroupCirculation1993876 SupplVI-65708500242
   PubMed Web of Science ®Google Scholar
• WongMStaszewskyLLatiniRSeverity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic dataJ Am Coll Cardiol2004432022715172407
   PubMed Web of Science ®Google Scholar
• XuYMenonVJugduttBICardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-receptor expression and IP3 receptor and PKCe proteinsJ Renin Angiotensin Aldosterone Syst200011849511967812
   PubMedGoogle Scholar
• YuCMTipoeGLWing-Hon LaiKEffects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarctionJ Am Coll Cardiol20013812071511583905
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKCHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet20033627778113678871
   PubMed Web of Science ®Google Scholar
• YusufSFrom the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosisAm J Cardiol2002892A18A25A11779516
   PubMed Web of Science ®Google Scholar
• ZannadFAllaFDoussetBLimitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales InvestigatorsCirculation20001022700611094035
   PubMed Web of Science ®Google Scholar